经皮左心耳封堵术后的抗凝/抗血小板药物治疗方案  

Anticoagulation/Antiplatelet Therapy Strategy after Left Atrial Appendage Occlusion

作　　者：仲程豪 杨兵[1] 周秀娟[1] ZHONG Chenghao;YANG Bing;ZHOU Xiujuan(Department of Cardiology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院心内科,南京210029

出　　处：《医学综述》2018年第14期2823-2827,共5页Medical Recapitulate

摘　　要：心房颤动患者的卒中风险显著增加,经皮左心耳封堵(LAAO)预防卒中的效果不差于口服华法林抗凝治疗。LAAO术后需使用抗凝和(或)抗血小板药物治疗,以预防装置表面血栓形成。然而在临床实践中,患者可能合并其他病症,或需要与其他心脏介入手术同时进行,围术期抗凝和(或)抗血小板药物治疗需要兼顾有效性和安全性。目前抗凝和(或)抗血小板药物治疗方案尚无指南推荐,且各种情况下的抗凝和(或)抗血小板药物治疗方案需进一步研究。Atrial fibrillation is associated with an increased risk for stroke. It is demonstrated that left atrial appendage occlusion（LAAO） is not inferior to warfarin for preventing stroke in atrial fibrillation. Anticoagulation/antiplatelet therapy is necessary to prevent thrombus formation on the device after a successful LAAO procedure. In clinical practice,however,LAAO may be performed in patients who will undertake other interventional therapy simultaneously or have other comorbidities. The efficacy and safety of different anticoagulation/antiplatelet therapy strategies should be taken into consideration during the perioperative period. At present,the strategy of anticoagulation/antiplatelet therapy has no guidelines,and the strategy of anticoagulation/antiplatelet therapy under different conditions needs further studies.

关 键 词：心房颤动 卒中 左心耳封堵 抗凝 抗血小板治疗 

分 类 号：R541.75[医药卫生—心血管疾病]